Enesi Pharma’s ImplaVax® platform shortlisted for Best New Vaccine Technology/Platform at the Vaccine Industry Excellence (ViE) Awards 2019

OXFORD, UK – 10 April 2019 – Enesi Pharma announces that its proprietary ImplaVax® solid dose, needle-free device and formulation technology has been shortlisted for the Best New Vaccine Technology/Platform Award, the winner of which will be revealed at the 12th Annual Vaccine Industry Excellence (ViE) Awards 2019 ceremony and gala dinner on 15 April. The Awards honour and recognize the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry and are a highlight of the World Vaccine Congress, taking place on 14-17 April in Washington, DC.

For the past 18 years, the World Vaccine Congress Washington has evolved and grown into the leading vaccines congress globally, with over 300 speakers and 1,500 attendees. The event is a leading forum for discussing how cutting-edge research efforts can be integrated with pharma, biotech, academia and government to produce more and better vaccines to the market. In addition, the congress is expanding into newer topic areas such as BioDefense, Big Data and Bioinformatics in a greater capacity, engaging more profiles from Army, Department of Defense, non-profits and national representatives in healthcare.